BioWorld

Jan. 17, 2012

Record Year for Royalty Deals Builds Optimism for 2012

Not everyone is upset about the turmoil in the equity markets. Last year was a record year for the sale of royalty streams and other structured product deals, in large part because of the lack of other options for biotechs. Read More

Too Many Trials Still Published At a Glacial Pace, or Not at All

Supposedly, academia's battle cry is "publish or perish." So why are so many clinical trials going unpublished? Read More

Week in Review

Word on the Street

Week in Washington

Biotech Restructurings, Expansions, Scale-Backs, Bankruptcies: Jan. 1 - Dec. 31, 2011

Biotech Lawsuits: Jan. 1 - Dec. 31, 2011

Money Raised By Biotech In 2012 Vs. 2011

Money Raised By Biotech: Jan. 1 - 13, 2012

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...